LCS Knee System
Depuy, Inc. · Decision date Oct 27, 2026
What did the FDA decide?
This 30-Day Notice for P830055/S378 records a process change at the DePuy Synthes manufacturing facility in Raynham, Massachusetts: introduction of an in-house X-ray inspection process. The device is the LCS® Knee System, classified as a semi-constrained, metal/polymer, mobile bearing patellofemorotibial knee prosthesis under product code NJL.
The supplement type is Process Change – Manufacturer/Sterilizer/Packager/Supplier, and the decision is OK30. The notice does not state what the X-ray inspection examines, which manufacturing steps it covers, or any resulting quality or safety outcomes. It is not a new approval of the knee system and does not establish clinical effectiveness.
FDA approval order statement
introduction of an in-house X-ray inspection process at DePuy Synthes manufacturing facility in Raynham, Massachusetts
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Oct 27, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P830055/S378
- Regulatory pathway
- PMA supplement
- Applicant
- Depuy, Inc.
- Product code
- NJL
- Decision code
- OK30
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, knee, patellofemorotibial, semi-constrained, metal/polymer, mobile bearing.
- Applicant
- Depuy, Inc.
- Product code
- NJL
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P830055/S374 · Related supplement
LCS(R) TOTAL KNEE SYSTEM, specifically ATTUNE Cruciate Retaining (CR), Posterior Stabilized (PS) and Revision Femoral C
P830055/S372 · Related supplement
ATTUNE Rotating Platform (RP) Total Knee System, ATTUNE Cementless Rotating Platform (RP) Knee System, ATTUNE Revision R
P830055/S376 · Related supplement
Attune Rotating Platform (RP) Total Knee System and the DePuy P.F.C. Sigma Rotating Platform (RP) Total Knee System an
P830055/S351 · Related supplement
Attune Revision Knee System
P830055/S375 · Related supplement
LCS Total Knee System
P830055/S378 received
Application receipt date recorded by FDA.
P830055/S380 · Related supplement
LCS Total Knee System
P830055/S377 · Related supplement
ATTUNE Rotating Platform (RP) Total Knee System, ATTUNE Revision Rotating Platform (RP) Total Knee System, and M.B.T. Re
P830055/S379 · Related supplement
ATTUNE Revision Knee System
P830055/S381 · Related supplement
ATTUNE Rotating Platform (RP) Total Knee System, and ATTUNE Revision Rotating Platform (RP) Knee System
P830055/S378 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P830055. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P830055
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Depuy, Inc. | PMA supplement | Sep 3, 2026 | FDA | |
| Depuy, Inc. | PMA supplement | Sep 9, 2026 | FDA | |
| Depuy, Inc. | PMA supplement | Sep 10, 2026 | FDA | |
Attune Revision Knee SystemP830055/S351 | Depuy, Inc. | PMA supplement | Sep 21, 2026 | FDA |
LCS Total Knee SystemP830055/S375 | Depuy, Inc. | PMA supplement | Sep 25, 2026 | FDA |
LCS Total Knee SystemP830055/S380 | Depuy, Inc. | PMA supplement | Oct 5, 2026 | FDA |
| Depuy, Inc. | PMA supplement | Oct 8, 2026 | FDA | |
ATTUNE Revision Knee SystemP830055/S379 | Depuy, Inc. | PMA supplement | Oct 9, 2026 | FDA |
| Depuy, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Explore the linked device profile
Other records with product code NJL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
NexGen LPS-Flex/LPS Mobile Bearing Knee SystemP060037/S100 | Zimmer, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Zimmer, Inc. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Depuy, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- P.O. Box 988, 700 Orthopaedic Dr., Warsaw, IN, 46581
Sources and methodology
- Original FDA record: P830055/S378
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






